This guideline covers how healthcare services for people with urological cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
This guideline covers how healthcare services for breast cancer should be organised. It aims to improve care for women with breast cancer by recommending which healthcare professionals should be involved in care.
This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
This guideline covers best practice in developing and delivering cancer services for adults. It aims to ensure that people with cancer, and their families and carers, are well informed, cared for and supported from before formal diagnosis onward.
This guideline covers how healthcare services for children and young people with cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
This guideline covers how healthcare services for adults with head and neck cancers should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
This guideline covers how healthcare services for people with skin cancers should be organised. It aims to improve diagnosis and care by recommending which healthcare professionals should be involved and at which stage.
This guideline covers how healthcare services for people with sarcoma should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa in adults and children
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children
Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults
Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
Proposed [GID-HST10019] Expected publication date: TBC
Proposed [GID-HST10022] Expected publication date: TBC
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
In development [GID-HST10011] Expected publication date: TBC
In development [GID-HST10015] Expected publication date: TBC
In development [GID-HST10026] Expected publication date: TBC
In development [GID-HST10017] Expected publication date: TBC
In development [GID-HST10010] Expected publication date: TBC
Proposed [GID-HST10023] Expected publication date: TBC
In development [GID-HST10009] Expected publication date: TBC
Proposed [GID-HST10020] Expected publication date: TBC
Proposed [GID-HST10028] Expected publication date: TBC
Technology appraisal [TA625] Published date: 04 March 2020
This guidance has been updated and replaced by NICE guideline NG47.
This guidance has been updated and replaced by NICE guideline NG151
Evidence-based recommendations on rituximab (MabThera) for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
Evidence-based recommendations on onhaled corticosteroids for treating chronic asthma in adults and children aged 12 years and over
Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome
Evidence-based recommendations on pemetrexed (Alimta) for treating non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on adalimumab (Humira) for the treatment of adults with plaque psoriasis
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)
NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the
Evidence-based recommendations on natalizumab (Tysabri) for highly active relapsing–remitting multiple sclerosis (MS) in adults
Evidence-based recommendations on stapled haemorrhoidopexy for treating haemorrhoids
Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma (bone marrow cancer)
Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12
Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults
Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)
Evidence-based recommendations on structural neuroimaging for treating first-episode psychosis
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer